Select therapeutic use:
Indications for E.E.S.:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
1.6g/day in 2, 3, or 4 evenly divided doses; max 4g/day. Legionnaires: 1.6–4g/day in divided doses.
Mild-to-moderate infections: 30–50mg/kg/day in 2, 3, or 4 evenly divided doses; may double dose in severe infections.
Concomitant cisapride, pimozide, ergotamine, dihydroergotamine.
Hepatic dysfunction. Proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); QT prolongation may occur, avoid. Myasthenia gravis. Elderly. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP3A (eg, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine). May potentiate or be potentiated by hexobarbital, phenytoin, valproate. May potentiate triazolam, midazolam, digoxin, theophylline, statins (rhabdomyolysis), sildenafil (reduce dose of sildenafil), colchicine (reduce starting dose of colchicine, max dose should be lowered; monitor). Hypotension, bradyarrhythmias, lactic acidosis with verapamil. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem). Increased anticoagulant effects with oral anticoagulants. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation.
Susp—100mL, pt; Granules—100mL, 200mL; Tabs—100